Lung Cancer Clincial Trials
MERCK (3475-799)
A Phase II Trial of Pembrolizumab in Combination with Doublet Chemotherapy and Radiotherapy for Participants with Unresectable, Locally Advanced Stage III Non-Small Cell Lung Cancer (KEYNOTE-799)
Learn more.
MERCK (3475-671)
A Phase III, Randomized, Double-Blind Trial of Platinum Doublet Chemotherapy +/- Pembrolizumab (MK-3475) as Neoadjuvant/Adjuvant Therapy for Participants with Resectable Stage IIB or IIIA Non-Small Cell Lung Cancer
Learn more.
MERCK (7902-007)
A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% (LEAP-007)
Learn more.
A151216 (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST). Testing for EGFR, ALK, PD-L1. Sponsor will pay for testing if no local results available.
Learn more.
A081105 (Sub-study of Alchemist)
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Learn more.
E4512 (Sub-study of Alchemist)
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Learn more.
LungMap
A Biomarker-Driven Master Protocol for Previously Treated Non-Small Cell Lung Cancer (LUNG-MAP)
Learn more.
CC003
Randomized Phase II/III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small Cell Lung Cancer
Learn more.
A081105 (Sub-study of ALCHEMIST)
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Learn more.
S1900A (Sub-study of LungMAP)
Rucaparib in Treating Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)
Learn more.
S1800A (Sub-study of LungMAP)
Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial)
Learn more.
S1400F (Sub-study of LungMAP)
Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer
Learn more.
AstraZeneca PACIFIC4
Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients (PACIFIC-4)
Learn more.
NanoPac 2020
Trial of NanoPac Intratumoral Injection in Lung Cancer
Learn more.
Merck 7339-012
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Learn more.
LU005
Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer
Learn more.